NO20052633L - Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases - Google Patents

Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases

Info

Publication number
NO20052633L
NO20052633L NO20052633A NO20052633A NO20052633L NO 20052633 L NO20052633 L NO 20052633L NO 20052633 A NO20052633 A NO 20052633A NO 20052633 A NO20052633 A NO 20052633A NO 20052633 L NO20052633 L NO 20052633L
Authority
NO
Norway
Prior art keywords
imaging
cardiovascular diseases
scavenger receptor
receptor antagonists
macrophage scavenger
Prior art date
Application number
NO20052633A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052633D0 (no
Inventor
Duncan Wynn
Ian Wilson
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20052633D0 publication Critical patent/NO20052633D0/no
Publication of NO20052633L publication Critical patent/NO20052633L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005Compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052633A 2002-12-06 2005-06-01 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases NO20052633L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228490.9A GB0228490D0 (en) 2002-12-06 2002-12-06 Novel imaging compounds
PCT/GB2003/005319 WO2004052357A1 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases

Publications (2)

Publication Number Publication Date
NO20052633D0 NO20052633D0 (no) 2005-06-01
NO20052633L true NO20052633L (no) 2005-07-06

Family

ID=9949200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052633A NO20052633L (no) 2002-12-06 2005-06-01 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases

Country Status (10)

Country Link
US (1) US20060239915A1 (https=)
EP (1) EP1567141A1 (https=)
JP (1) JP2006514945A (https=)
CN (1) CN1744890A (https=)
AU (1) AU2003292384B2 (https=)
CA (1) CA2508663A1 (https=)
GB (1) GB0228490D0 (https=)
NO (1) NO20052633L (https=)
RU (1) RU2005116983A (https=)
WO (1) WO2004052357A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7886497B2 (en) 2003-12-02 2011-02-15 Valinge Innovation Ab Floorboard, system and method for forming a flooring, and a flooring formed thereof
GB0428020D0 (en) 2004-12-22 2005-01-26 Amersham Health As Stabilisation of radiopharmaceutical precursors
WO2006077901A1 (ja) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf発現阻害剤
RU2474435C2 (ru) * 2007-11-07 2013-02-10 Джи-И Хелткер БВ Стабилизация радиофармацевтических композиций
US11725395B2 (en) 2009-09-04 2023-08-15 Välinge Innovation AB Resilient floor
EP2473687B1 (en) 2009-09-04 2019-04-24 Välinge Innovation AB A method of assembling resilient floorboards which are provided with a mechanical locking system
PT3115161T (pt) 2011-08-29 2020-02-06 Ceraloc Innovation Ab Sistema de encaixe mecânico para painéis de pavimento
PT3358101T (pt) 2013-03-25 2020-01-21 Vaelinge Innovation Ab Tábuas de piso providas de um sistema de bloqueio mecânico e método para produzir um sistema de bloqueio deste tipo
EP3802514B1 (en) * 2018-06-01 2022-08-03 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
MXPA02000123A (es) * 1999-06-24 2002-07-02 Smithkline Beecham Corp Antagonistas de receptor depurador de macrofago.
WO2001098264A1 (en) * 2000-06-21 2001-12-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
EP1377321A4 (en) * 2001-02-23 2006-01-11 Bristol Myers Squibb Co RECOVERY ANTAGONISTS RECEIVING DETECTABLE MACROPHAGE RECEPTORS FOR THE IDENTIFICATION OF ATHEROSCLEROSIS AND VULNERABLE PLAQUE BY IMAGING

Also Published As

Publication number Publication date
JP2006514945A (ja) 2006-05-18
NO20052633D0 (no) 2005-06-01
EP1567141A1 (en) 2005-08-31
CA2508663A1 (en) 2004-06-24
RU2005116983A (ru) 2006-02-27
US20060239915A1 (en) 2006-10-26
AU2003292384A1 (en) 2004-06-30
AU2003292384B2 (en) 2007-04-19
GB0228490D0 (en) 2003-01-08
CN1744890A (zh) 2006-03-08
WO2004052357A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
NO20074895L (no) Isoksazolin derivat og ny fremgangsmate for fremstilling derav
NO20085338L (no) Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
NO20071667L (no) Farmasoytisk preparat omfattende levetiracetam og fremgangsmate for fremstilling av preparatet
SV2008003074A (es) Piridin[3,4-b] pirazinonas
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
EP1933883A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF IGA- AND IGM-MEDICINED KIDNEY DISEASES
NO20092584L (no) Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
NO20045281L (no) Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
JO2984B1 (ar) تركيب الجسم المضاد her2
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
NO20043367L (no) Oralt farmasoytisk preparat
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
UY28922A1 (es) Ligandos del receptor cb1 útiles en el tratamiento de dolor y/u otros síntomas o enfermedades relacionadas; compuestos farmacéuticos y su preparación.
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
DE602007011302D1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
NO20045486L (no) Nye forbindelser og deres anvendelse
SV2005002099A (es) " nuevos compuestos " ref. pc 32096a

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application